KR102338119B1 - Hub complex composition - Google Patents
Hub complex composition Download PDFInfo
- Publication number
- KR102338119B1 KR102338119B1 KR1020190178987A KR20190178987A KR102338119B1 KR 102338119 B1 KR102338119 B1 KR 102338119B1 KR 1020190178987 A KR1020190178987 A KR 1020190178987A KR 20190178987 A KR20190178987 A KR 20190178987A KR 102338119 B1 KR102338119 B1 KR 102338119B1
- Authority
- KR
- South Korea
- Prior art keywords
- composition
- vaginal
- health
- present
- weight
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 93
- 206010027304 Menopausal symptoms Diseases 0.000 claims abstract description 36
- 239000004615 ingredient Substances 0.000 claims abstract description 20
- 230000006872 improvement Effects 0.000 claims abstract description 19
- 206010047791 Vulvovaginal dryness Diseases 0.000 claims abstract description 15
- 235000008694 Humulus lupulus Nutrition 0.000 claims abstract description 11
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 9
- 235000015872 dietary supplement Nutrition 0.000 claims abstract description 4
- 208000024891 symptom Diseases 0.000 claims description 21
- 235000013311 vegetables Nutrition 0.000 claims description 15
- 229930003231 vitamin Natural products 0.000 claims description 8
- 239000011782 vitamin Substances 0.000 claims description 8
- 235000013343 vitamin Nutrition 0.000 claims description 8
- 229940088594 vitamin Drugs 0.000 claims description 8
- 239000004480 active ingredient Substances 0.000 claims description 7
- 235000013406 prebiotics Nutrition 0.000 claims description 7
- 239000011701 zinc Substances 0.000 claims description 7
- 229910052725 zinc Inorganic materials 0.000 claims description 7
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 6
- 241000218691 Cupressaceae Species 0.000 claims description 4
- 238000000034 method Methods 0.000 claims description 4
- 201000000079 gynecomastia Diseases 0.000 claims description 2
- 206010020649 Hyperkeratosis Diseases 0.000 claims 3
- 208000001126 Keratosis Diseases 0.000 claims 3
- 230000036541 health Effects 0.000 abstract description 33
- 206010060800 Hot flush Diseases 0.000 abstract description 10
- 241000196324 Embryophyta Species 0.000 abstract description 9
- 208000033830 Hot Flashes Diseases 0.000 abstract description 9
- 239000006041 probiotic Substances 0.000 abstract description 3
- 235000018291 probiotics Nutrition 0.000 abstract description 3
- 241000218218 Ficus <angiosperm> Species 0.000 abstract description 2
- 235000008730 Ficus carica Nutrition 0.000 abstract description 2
- 239000002131 composite material Substances 0.000 abstract description 2
- 230000000694 effects Effects 0.000 description 31
- 230000000052 comparative effect Effects 0.000 description 29
- 230000009245 menopause Effects 0.000 description 17
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 12
- 239000000284 extract Substances 0.000 description 12
- 210000003097 mucus Anatomy 0.000 description 12
- 244000025221 Humulus lupulus Species 0.000 description 11
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 10
- 206010010774 Constipation Diseases 0.000 description 10
- 241000700159 Rattus Species 0.000 description 9
- 235000013402 health food Nutrition 0.000 description 9
- 229940011871 estrogen Drugs 0.000 description 8
- 239000000262 estrogen Substances 0.000 description 8
- 230000001965 increasing effect Effects 0.000 description 8
- 238000011282 treatment Methods 0.000 description 8
- 229940088597 hormone Drugs 0.000 description 7
- 239000005556 hormone Substances 0.000 description 7
- 239000002023 wood Substances 0.000 description 7
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- 206010016825 Flushing Diseases 0.000 description 6
- 235000012000 cholesterol Nutrition 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 235000013399 edible fruits Nutrition 0.000 description 6
- 229960005309 estradiol Drugs 0.000 description 6
- 238000011156 evaluation Methods 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- 230000028327 secretion Effects 0.000 description 6
- 235000016804 zinc Nutrition 0.000 description 6
- 238000010171 animal model Methods 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 238000000605 extraction Methods 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 210000002429 large intestine Anatomy 0.000 description 5
- 238000002156 mixing Methods 0.000 description 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- 208000017667 Chronic Disease Diseases 0.000 description 4
- 235000007516 Chrysanthemum Nutrition 0.000 description 4
- 244000189548 Chrysanthemum x morifolium Species 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 206010019233 Headaches Diseases 0.000 description 4
- 206010022998 Irritability Diseases 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- 235000011399 aloe vera Nutrition 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 231100000869 headache Toxicity 0.000 description 4
- 230000001939 inductive effect Effects 0.000 description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
- 238000009806 oophorectomy Methods 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- LPEPZZAVFJPLNZ-SFHVURJKSA-N sophoraflavanone B Chemical compound C1([C@@H]2CC(=O)C=3C(O)=CC(O)=C(C=3O2)CC=C(C)C)=CC=C(O)C=C1 LPEPZZAVFJPLNZ-SFHVURJKSA-N 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 241001116389 Aloe Species 0.000 description 3
- 208000019901 Anxiety disease Diseases 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 3
- 208000024172 Cardiovascular disease Diseases 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 108010007622 LDL Lipoproteins Proteins 0.000 description 3
- 102000007330 LDL Lipoproteins Human genes 0.000 description 3
- 208000017657 Menopausal disease Diseases 0.000 description 3
- 102000015728 Mucins Human genes 0.000 description 3
- 108010063954 Mucins Proteins 0.000 description 3
- 208000001132 Osteoporosis Diseases 0.000 description 3
- 208000002193 Pain Diseases 0.000 description 3
- 206010036618 Premenstrual syndrome Diseases 0.000 description 3
- 230000036506 anxiety Effects 0.000 description 3
- 235000021028 berry Nutrition 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 235000013376 functional food Nutrition 0.000 description 3
- 230000007413 intestinal health Effects 0.000 description 3
- 210000004347 intestinal mucosa Anatomy 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 210000003205 muscle Anatomy 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 230000036407 pain Effects 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 208000019116 sleep disease Diseases 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- 208000011580 syndromic disease Diseases 0.000 description 3
- 230000002195 synergetic effect Effects 0.000 description 3
- -1 that is Substances 0.000 description 3
- 240000004731 Acer pseudoplatanus Species 0.000 description 2
- 235000002754 Acer pseudoplatanus Nutrition 0.000 description 2
- 208000000044 Amnesia Diseases 0.000 description 2
- 208000006820 Arthralgia Diseases 0.000 description 2
- 206010003694 Atrophy Diseases 0.000 description 2
- 208000008035 Back Pain Diseases 0.000 description 2
- 201000004569 Blindness Diseases 0.000 description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 244000019459 Cynara cardunculus Species 0.000 description 2
- 235000019106 Cynara scolymus Nutrition 0.000 description 2
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 2
- 101710088194 Dehydrogenase Proteins 0.000 description 2
- 239000004375 Dextrin Substances 0.000 description 2
- 229920001353 Dextrin Polymers 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 208000008454 Hyperhidrosis Diseases 0.000 description 2
- 241000186660 Lactobacillus Species 0.000 description 2
- 229920002774 Maltodextrin Polymers 0.000 description 2
- 239000005913 Maltodextrin Substances 0.000 description 2
- 208000026139 Memory disease Diseases 0.000 description 2
- 208000037093 Menstruation Disturbances Diseases 0.000 description 2
- 208000000112 Myalgia Diseases 0.000 description 2
- 235000008331 Pinus X rigitaeda Nutrition 0.000 description 2
- 235000011613 Pinus brutia Nutrition 0.000 description 2
- 241000018646 Pinus brutia Species 0.000 description 2
- 235000006485 Platanus occidentalis Nutrition 0.000 description 2
- 208000001871 Tachycardia Diseases 0.000 description 2
- 229930003451 Vitamin B1 Natural products 0.000 description 2
- 229930003268 Vitamin C Natural products 0.000 description 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 235000016520 artichoke thistle Nutrition 0.000 description 2
- 230000037444 atrophy Effects 0.000 description 2
- 230000003796 beauty Effects 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 2
- NVEQFIOZRFFVFW-RGCMKSIDSA-N caryophyllene oxide Chemical group C=C1CC[C@H]2O[C@]2(C)CC[C@H]2C(C)(C)C[C@@H]21 NVEQFIOZRFFVFW-RGCMKSIDSA-N 0.000 description 2
- 210000000038 chest Anatomy 0.000 description 2
- 239000001905 cichorium intybus l. root extract Substances 0.000 description 2
- 210000001072 colon Anatomy 0.000 description 2
- 239000002537 cosmetic Substances 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 235000019425 dextrin Nutrition 0.000 description 2
- 208000002173 dizziness Diseases 0.000 description 2
- 201000006549 dyspepsia Diseases 0.000 description 2
- 230000002124 endocrine Effects 0.000 description 2
- 229930182833 estradiol Natural products 0.000 description 2
- 206010016256 fatigue Diseases 0.000 description 2
- 235000019162 flavin adenine dinucleotide Nutrition 0.000 description 2
- 239000011714 flavin adenine dinucleotide Substances 0.000 description 2
- VWWQXMAJTJZDQX-UYBVJOGSSA-N flavin adenine dinucleotide Chemical compound C1=NC2=C(N)N=CN=C2N1[C@@H]([C@H](O)[C@@H]1O)O[C@@H]1CO[P@](O)(=O)O[P@@](O)(=O)OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C2=NC(=O)NC(=O)C2=NC2=C1C=C(C)C(C)=C2 VWWQXMAJTJZDQX-UYBVJOGSSA-N 0.000 description 2
- 229940093632 flavin-adenine dinucleotide Drugs 0.000 description 2
- 229930003935 flavonoid Natural products 0.000 description 2
- 150000002215 flavonoids Chemical class 0.000 description 2
- 235000017173 flavonoids Nutrition 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- DCAYPVUWAIABOU-UHFFFAOYSA-N hexadecane Chemical compound CCCCCCCCCCCCCCCC DCAYPVUWAIABOU-UHFFFAOYSA-N 0.000 description 2
- 235000009200 high fat diet Nutrition 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- CJWQYWQDLBZGPD-UHFFFAOYSA-N isoflavone Natural products C1=C(OC)C(OC)=CC(OC)=C1C1=COC2=C(C=CC(C)(C)O3)C3=C(OC)C=C2C1=O CJWQYWQDLBZGPD-UHFFFAOYSA-N 0.000 description 2
- 150000002515 isoflavone derivatives Chemical class 0.000 description 2
- 235000008696 isoflavones Nutrition 0.000 description 2
- 239000004310 lactic acid Substances 0.000 description 2
- 235000014655 lactic acid Nutrition 0.000 description 2
- 229940039696 lactobacillus Drugs 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 230000033001 locomotion Effects 0.000 description 2
- RDOIQAHITMMDAJ-UHFFFAOYSA-N loperamide Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(C(=O)N(C)C)CCN(CC1)CCC1(O)C1=CC=C(Cl)C=C1 RDOIQAHITMMDAJ-UHFFFAOYSA-N 0.000 description 2
- 229960001571 loperamide Drugs 0.000 description 2
- 208000018769 loss of vision Diseases 0.000 description 2
- 231100000864 loss of vision Toxicity 0.000 description 2
- 229940035034 maltodextrin Drugs 0.000 description 2
- 230000006984 memory degeneration Effects 0.000 description 2
- 206010027175 memory impairment Diseases 0.000 description 2
- 208000023060 memory loss Diseases 0.000 description 2
- 231100000544 menstrual irregularity Toxicity 0.000 description 2
- 230000005906 menstruation Effects 0.000 description 2
- 230000003340 mental effect Effects 0.000 description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 2
- 230000027939 micturition Effects 0.000 description 2
- 208000013465 muscle pain Diseases 0.000 description 2
- 210000000944 nerve tissue Anatomy 0.000 description 2
- 235000021590 normal diet Nutrition 0.000 description 2
- 230000002611 ovarian Effects 0.000 description 2
- 210000001672 ovary Anatomy 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 2
- 230000003248 secreting effect Effects 0.000 description 2
- 208000022925 sleep disturbance Diseases 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- YHWNASRGLKJRJJ-UHFFFAOYSA-N sophoraflavanone B Natural products C1C(=O)C2=C(O)C(CC=C(C)C)=C(O)C=C2OC1C1=CC=C(O)C=C1 YHWNASRGLKJRJJ-UHFFFAOYSA-N 0.000 description 2
- 230000035882 stress Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000035900 sweating Effects 0.000 description 2
- 230000006794 tachycardia Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 229960003495 thiamine Drugs 0.000 description 2
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 2
- 230000004393 visual impairment Effects 0.000 description 2
- 235000010374 vitamin B1 Nutrition 0.000 description 2
- 239000011691 vitamin B1 Substances 0.000 description 2
- 235000019154 vitamin C Nutrition 0.000 description 2
- 239000011718 vitamin C Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 239000000811 xylitol Substances 0.000 description 2
- 229960002675 xylitol Drugs 0.000 description 2
- 235000010447 xylitol Nutrition 0.000 description 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 2
- VPDZRSSKICPUEY-GQRSATBHSA-N (+)-Bicyclogermacrene Natural products CC1(C)[C@@H]/2[C@H]1CC/C(/C)=C\CC/C(/C)=C\2 VPDZRSSKICPUEY-GQRSATBHSA-N 0.000 description 1
- LUEWUZLMQUOBSB-FSKGGBMCSA-N (2s,3s,4s,5s,6r)-2-[(2r,3s,4r,5r,6s)-6-[(2r,3s,4r,5s,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5s,6r)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-4,5-dihydroxy-2-(hydroxymethyl)oxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@@H](O[C@@H]2[C@H](O[C@@H](OC3[C@H](O[C@@H](O)[C@@H](O)[C@H]3O)CO)[C@@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O LUEWUZLMQUOBSB-FSKGGBMCSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- KPGXRSRHYNQIFN-UHFFFAOYSA-L 2-oxoglutarate(2-) Chemical compound [O-]C(=O)CCC(=O)C([O-])=O KPGXRSRHYNQIFN-UHFFFAOYSA-L 0.000 description 1
- NVEQFIOZRFFVFW-UHFFFAOYSA-N 9-epi-beta-caryophyllene oxide Natural products C=C1CCC2OC2(C)CCC2C(C)(C)CC21 NVEQFIOZRFFVFW-UHFFFAOYSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 206010000060 Abdominal distension Diseases 0.000 description 1
- AJNRZGCOXRHMEZ-UHFFFAOYSA-N Agnuside Natural products OCC1OC(OC2OC=CC3CC=C(COC(=O)c4ccc(O)cc4)C23)C(O)C(O)C1O AJNRZGCOXRHMEZ-UHFFFAOYSA-N 0.000 description 1
- 244000144927 Aloe barbadensis Species 0.000 description 1
- 235000002961 Aloe barbadensis Nutrition 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- JMGZEFIQIZZSBH-UHFFFAOYSA-N Bioquercetin Natural products CC1OC(OCC(O)C2OC(OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5)C(O)C2O)C(O)C(O)C1O JMGZEFIQIZZSBH-UHFFFAOYSA-N 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 241001107116 Castanospermum australe Species 0.000 description 1
- 241000195493 Cryptophyta Species 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- 206010060891 General symptom Diseases 0.000 description 1
- 229920002581 Glucomannan Polymers 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010021639 Incontinence Diseases 0.000 description 1
- YKGCBLWILMDSAV-GOSISDBHSA-N Isoxanthohumol Natural products O(C)c1c2C(=O)C[C@H](c3ccc(O)cc3)Oc2c(C/C=C(\C)/C)c(O)c1 YKGCBLWILMDSAV-GOSISDBHSA-N 0.000 description 1
- 244000060701 Kaempferia pandurata Species 0.000 description 1
- 102000011782 Keratins Human genes 0.000 description 1
- 108010076876 Keratins Proteins 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 206010027940 Mood altered Diseases 0.000 description 1
- 206010029216 Nervousness Diseases 0.000 description 1
- JYDNKGUBLIKNAM-UHFFFAOYSA-N Oxyallobutulin Natural products C1CC(=O)C(C)(C)C2CCC3(C)C4(C)CCC5(CO)CCC(C(=C)C)C5C4CCC3C21C JYDNKGUBLIKNAM-UHFFFAOYSA-N 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- 235000002789 Panax ginseng Nutrition 0.000 description 1
- 244000134552 Plantago ovata Species 0.000 description 1
- 235000003421 Plantago ovata Nutrition 0.000 description 1
- 239000009223 Psyllium Substances 0.000 description 1
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- JMFSHKGXVSAJFY-UHFFFAOYSA-N Saponaretin Natural products OCC(O)C1OC(Oc2c(O)cc(O)c3C(=O)C=C(Oc23)c4ccc(O)cc4)C(O)C1O JMFSHKGXVSAJFY-UHFFFAOYSA-N 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000014701 Transketolase Human genes 0.000 description 1
- 108010043652 Transketolase Proteins 0.000 description 1
- 206010046543 Urinary incontinence Diseases 0.000 description 1
- 208000002495 Uterine Neoplasms Diseases 0.000 description 1
- 206010046788 Uterine haemorrhage Diseases 0.000 description 1
- 235000016390 Uvaria chamae Nutrition 0.000 description 1
- 229930003270 Vitamin B Natural products 0.000 description 1
- 229930003471 Vitamin B2 Natural products 0.000 description 1
- 235000001667 Vitex agnus castus Nutrition 0.000 description 1
- 244000063464 Vitex agnus-castus Species 0.000 description 1
- MOZJVOCOKZLBQB-UHFFFAOYSA-N Vitexin Natural products OCC1OC(Oc2c(O)c(O)cc3C(=O)C=C(Oc23)c4ccc(O)cc4)C(O)C(O)C1O MOZJVOCOKZLBQB-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- GLACGTLACKLUJX-QNAXTHAFSA-N agnuside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@H]1[C@@H]2C(COC(=O)C=3C=CC(O)=CC=3)=C[C@@H](O)[C@@H]2C=CO1 GLACGTLACKLUJX-QNAXTHAFSA-N 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- UTDFQMAXCUGNJR-UHFFFAOYSA-N aucubin Natural products OCC1OC(Oc2ccoc2C3C(O)CCC3O)C(O)C(O)C1O UTDFQMAXCUGNJR-UHFFFAOYSA-N 0.000 description 1
- RJWJHRPNHPHBRN-FKVJWERZSA-N aucubin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@H]1[C@@H]2C(CO)=C[C@@H](O)[C@@H]2C=CO1 RJWJHRPNHPHBRN-FKVJWERZSA-N 0.000 description 1
- 238000005452 bending Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- FVWJYYTZTCVBKE-ROUWMTJPSA-N betulin Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(CO)CC[C@@H](C(=C)C)[C@@H]5[C@H]4CC[C@@H]3[C@]21C FVWJYYTZTCVBKE-ROUWMTJPSA-N 0.000 description 1
- MVIRREHRVZLANQ-UHFFFAOYSA-N betulin Natural products CC(=O)OC1CCC2(C)C(CCC3(C)C2CC=C4C5C(CCC5(CO)CCC34C)C(=C)C)C1(C)C MVIRREHRVZLANQ-UHFFFAOYSA-N 0.000 description 1
- VPDZRSSKICPUEY-JEPMYXAXSA-N bicyclogermacrene Chemical compound C1CC(/C)=C/CC\C(C)=C\[C@@H]2C(C)(C)[C@H]12 VPDZRSSKICPUEY-JEPMYXAXSA-N 0.000 description 1
- RXARZHLXLNWPFG-UHFFFAOYSA-N bicyclogermacrene Natural products CC1=C2C3C(CCC2=CCC1)C3(C)C RXARZHLXLNWPFG-UHFFFAOYSA-N 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 235000021279 black bean Nutrition 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 230000003925 brain function Effects 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- RSYBQKUNBFFNDO-UHFFFAOYSA-N caryophyllene oxide Natural products CC1(C)CC2C(=C)CCC3OC3(C)CCC12C RSYBQKUNBFFNDO-UHFFFAOYSA-N 0.000 description 1
- PJQLSMYMOKWUJG-UHFFFAOYSA-N casticin Chemical compound C1=C(O)C(OC)=CC=C1C1=C(OC)C(=O)C2=C(O)C(OC)=C(OC)C=C2O1 PJQLSMYMOKWUJG-UHFFFAOYSA-N 0.000 description 1
- 230000001925 catabolic effect Effects 0.000 description 1
- 210000004534 cecum Anatomy 0.000 description 1
- CCWSQXBMKLEALQ-WMZOPIPTSA-N centaureidin Natural products CO[C@@H]1[C@@H](Oc2cc(O)c(OC)c(O)c2C1=O)c3ccc(OC)c(O)c3 CCWSQXBMKLEALQ-WMZOPIPTSA-N 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000035606 childbirth Effects 0.000 description 1
- 229960004106 citric acid Drugs 0.000 description 1
- 239000005515 coenzyme Substances 0.000 description 1
- 230000000112 colonic effect Effects 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000013872 defecation Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 230000008451 emotion Effects 0.000 description 1
- 230000037149 energy metabolism Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000003912 environmental pollution Methods 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- IVTMALDHFAHOGL-UHFFFAOYSA-N eriodictyol 7-O-rutinoside Natural products OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C=C3C(C(C(O)=C(O3)C=3C=C(O)C(O)=CC=3)=O)=C(O)C=2)O1 IVTMALDHFAHOGL-UHFFFAOYSA-N 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- 102000015694 estrogen receptors Human genes 0.000 description 1
- 108010038795 estrogen receptors Proteins 0.000 description 1
- DTPRTOXMYKYSIJ-UHFFFAOYSA-N eupatorin Natural products C1=C(O)C(OC)=CC=C1C1=CC(=O)C2=CC(OC)=C(OC)C=C2O1 DTPRTOXMYKYSIJ-UHFFFAOYSA-N 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 230000004720 fertilization Effects 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- ZXUTYCBDXZZBBB-UHFFFAOYSA-N formaldehyde;phosphoric acid Chemical compound O=C.OP(O)(O)=O ZXUTYCBDXZZBBB-UHFFFAOYSA-N 0.000 description 1
- FTSSQIKWUOOEGC-RULYVFMPSA-N fructooligosaccharide Chemical compound OC[C@H]1O[C@@](CO)(OC[C@@]2(OC[C@@]3(OC[C@@]4(OC[C@@]5(OC[C@@]6(OC[C@@]7(OC[C@@]8(OC[C@@]9(OC[C@@]%10(OC[C@@]%11(O[C@H]%12O[C@H](CO)[C@@H](O)[C@H](O)[C@H]%12O)O[C@H](CO)[C@@H](O)[C@@H]%11O)O[C@H](CO)[C@@H](O)[C@@H]%10O)O[C@H](CO)[C@@H](O)[C@@H]9O)O[C@H](CO)[C@@H](O)[C@@H]8O)O[C@H](CO)[C@@H](O)[C@@H]7O)O[C@H](CO)[C@@H](O)[C@@H]6O)O[C@H](CO)[C@@H](O)[C@@H]5O)O[C@H](CO)[C@@H](O)[C@@H]4O)O[C@H](CO)[C@@H](O)[C@@H]3O)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@@H](O)[C@@H]1O FTSSQIKWUOOEGC-RULYVFMPSA-N 0.000 description 1
- 229940107187 fructooligosaccharide Drugs 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 229940046240 glucomannan Drugs 0.000 description 1
- 229960001031 glucose Drugs 0.000 description 1
- 230000003779 hair growth Effects 0.000 description 1
- 230000008821 health effect Effects 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 230000036074 healthy skin Effects 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 208000024798 heartburn Diseases 0.000 description 1
- 238000002657 hormone replacement therapy Methods 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 230000003871 intestinal function Effects 0.000 description 1
- 230000008991 intestinal motility Effects 0.000 description 1
- YKGCBLWILMDSAV-SFHVURJKSA-N isoxanthohumol Chemical compound C1([C@H]2OC=3C(CC=C(C)C)=C(O)C=C(C=3C(=O)C2)OC)=CC=C(O)C=C1 YKGCBLWILMDSAV-SFHVURJKSA-N 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 108010022197 lipoprotein cholesterol Proteins 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 238000005461 lubrication Methods 0.000 description 1
- 229960002160 maltose Drugs 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 238000000968 medical method and process Methods 0.000 description 1
- 230000004630 mental health Effects 0.000 description 1
- 230000006996 mental state Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000007510 mood change Effects 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 235000019462 natural additive Nutrition 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 210000004798 organs belonging to the digestive system Anatomy 0.000 description 1
- 230000016087 ovulation Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 238000010422 painting Methods 0.000 description 1
- 239000008055 phosphate buffer solution Substances 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 230000003128 phytoestrogenic effect Effects 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 229930008679 prenylflavonoid Natural products 0.000 description 1
- 150000007951 prenylflavonoids Chemical class 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000022558 protein metabolic process Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 229940070687 psyllium Drugs 0.000 description 1
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 1
- FDRQPMVGJOQVTL-UHFFFAOYSA-N quercetin rutinoside Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 FDRQPMVGJOQVTL-UHFFFAOYSA-N 0.000 description 1
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 238000006722 reduction reaction Methods 0.000 description 1
- 230000012121 regulation of immune response Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000009256 replacement therapy Methods 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- IKGXIBQEEMLURG-BKUODXTLSA-N rutin Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@@H]1OC[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-BKUODXTLSA-N 0.000 description 1
- ALABRVAAKCSLSC-UHFFFAOYSA-N rutin Natural products CC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5 ALABRVAAKCSLSC-UHFFFAOYSA-N 0.000 description 1
- 235000005493 rutin Nutrition 0.000 description 1
- 229960004555 rutoside Drugs 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 230000036299 sexual function Effects 0.000 description 1
- 238000004088 simulation Methods 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 230000009759 skin aging Effects 0.000 description 1
- 238000013223 sprague-dawley female rat Methods 0.000 description 1
- 238000013222 sprague-dawley male rat Methods 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000004906 toe nail Anatomy 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 210000002229 urogenital system Anatomy 0.000 description 1
- 206010046766 uterine cancer Diseases 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
- 235000019164 vitamin B2 Nutrition 0.000 description 1
- 239000011716 vitamin B2 Substances 0.000 description 1
- 235000019158 vitamin B6 Nutrition 0.000 description 1
- 239000011726 vitamin B6 Substances 0.000 description 1
- 229940011671 vitamin b6 Drugs 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- HKMZDYJMJDPXRP-UHFFFAOYSA-N vitexicarpin Natural products OC1=C2C(C(=C(OC2=CC(=C1OC)OC)C1=CC(=CC(=C1)OC)O)OC)=O HKMZDYJMJDPXRP-UHFFFAOYSA-N 0.000 description 1
- SGEWCQFRYRRZDC-VPRICQMDSA-N vitexin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1C1=C(O)C=C(O)C2=C1OC(C=1C=CC(O)=CC=1)=CC2=O SGEWCQFRYRRZDC-VPRICQMDSA-N 0.000 description 1
- PZKISQRTNNHUGF-UHFFFAOYSA-N vitexine Natural products OC1C(O)C(O)C(CO)OC1OC1=C(O)C=C(O)C2=C1OC(C=1C=CC(O)=CC=1)=CC2=O PZKISQRTNNHUGF-UHFFFAOYSA-N 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
- 230000005186 women's health Effects 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/489—Sophora, e.g. necklacepod or mamani
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/30—Zinc; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/60—Moraceae (Mulberry family), e.g. breadfruit or fig
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/10—Washing or bathing preparations
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/302—Foods, ingredients or supplements having a functional effect on health having a modulating effect on age
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K2035/11—Medicinal preparations comprising living procariotic cells
- A61K2035/115—Probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Reproductive Health (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Endocrinology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Nutrition Science (AREA)
- Gynecology & Obstetrics (AREA)
- Birds (AREA)
- Inorganic Chemistry (AREA)
- Dermatology (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
본 발명은 식물성 천연성분 조성물에 관한 것으로서, 더욱 상세하게는 특정 식물성 천연성분으로 회화나무, 순결나무, 홉 중에서 선택된 2성분 이상을 함유하는 복합성분 조성물로서, 특히 여성갱년기 증상의 개선 등 건강증진용 조성물로 유용한 프로바이오틱스를 함유하는 식물성 천연 복합성분 조성물에 관한 것이다. 이러한 본 발명의 조성물은 안면홍조, 질 건강, 질 건조증 및 질 pH 개선, 갱년기 증상 개선용 건강보조식품이나 이를 치료하는 약학적 조성물로 유용하다.The present invention relates to a plant natural ingredient composition, and more particularly, as a specific plant natural ingredient, a composite ingredient composition containing at least two components selected from among fig trees, chastity trees, and hops, especially for health promotion such as improvement of female menopausal symptoms It relates to a plant-natural complex component composition containing probiotics useful as a composition. The composition of the present invention is useful as a health supplement for improving hot flashes, vaginal health, vaginal dryness and vaginal pH, improving menopausal symptoms or a pharmaceutical composition for treating the same.
Description
본 발명은 식물성 천연성분 조성물에 관한 것으로서, 더욱 상세하게는 특정 식물성 천연성분으로 회화나무, 순결나무, 홉 중에서 선택된 2성분 이상을 함유하는 복합성분 조성물로서, 특히 여성갱년기 증상의 개선 등 건강증진용 조성물로 유용한 프로바이오틱스를 함유하는 식물성 천연 복합성분 조성물에 관한 것이다.The present invention relates to a plant natural ingredient composition, and more particularly, as a specific plant natural ingredient, a composite ingredient composition containing at least two components selected from among fig trees, chastity trees, and hops, especially for health promotion such as improvement of female menopausal symptoms It relates to a plant-natural complex component composition containing probiotics useful as a composition.
산업의 발달로 생활수준이 향상되고 편리함도 한층 좋아지고 있지만, 이러한 산업발달 과정에서 각종 환경오염이 발생하고, 사회경쟁이 치열해지면서 생활 스트레스, 운동량 부족 등의 문제가 발생하고 있다.With the development of industry, the standard of living has improved and convenience is getting better. However, in the process of industrial development, various environmental pollution occurs, and as social competition intensifies, problems such as life stress and lack of exercise are occurring.
또한, 이러한 생활환경의 변화로 인해 식습관도 변화고 육식이 급격하게 늘어나며, 영양 불균형 등의 이유로 각종 성인병이나 만성질환이 급속히 늘어나고 있다. 만성질환은 현재까지 의학적 방법이 주된 치료 방법으로 이용되어 왔지만, 치료에 한계가 있는데다가 특히, 치료약의 부작용이나 일시적 또는 부분적인 치료효과 등으로 인해 그 만성질환이나 성인병 등의 치료에 많은 한계가 노정되고 있다. In addition, due to these changes in the living environment, dietary habits are also changed, meat consumption is rapidly increasing, and various adult diseases and chronic diseases are rapidly increasing due to nutritional imbalances and the like. Although medical methods have been used as the main treatment method for chronic diseases, there are limitations in treatment, and in particular, there are many limitations in the treatment of chronic diseases or adult diseases due to side effects or temporary or partial therapeutic effects of therapeutic drugs. is becoming
그런데 식품 중에 함유된 유효성분에 의한 건강증진 및 질병예방 효과들이 여러 연구로부터 증명되면서, 매우 느린 속도이기는 하지만 천연 건강식품이나 음식의 조절 등을 통해 성인병과 만성질환의 예방이 점차 가능해지고 있다.However, as the effects of health promotion and disease prevention by the active ingredients contained in food have been proven by several studies, the prevention of adult diseases and chronic diseases is gradually becoming possible through natural health food or food control, although at a very slow rate.
아울러서, 현대 산업화로 인하여 경제적 수준이 향상되고 의학이 발달함으로써 인간의 수명이 연장되어 노령인구가 증가하고 있다. 따라서 노령인구의 건강과 삶의 질을 향상시키기 위한 연구들이 이루어지고 있다.In addition, due to modern industrialization, the economic level is improved and the human lifespan is extended due to the development of medicine, and the elderly population is increasing. Therefore, studies are being conducted to improve the health and quality of life of the elderly.
특히, 여성의 경우 40대 이후 서서히 시작되는 갱년기 증상으로 인해 신체적 및 정신적 어려움을 겪고 있다. 전체 여성의 약 20%가 겪는 갱년기는 노화 현상의 하나로 개인별로 차이는 있지만 중년이 지나면서 서서히 시작되는데, 평균수명이 연장됨으로써 여성 일생의 상당 부분을 갱년기로 보내야 하는 문제가 있다.In particular, in the case of women, they are experiencing physical and mental difficulties due to the symptoms of menopause that start slowly after the age of 40. Menopause, which approximately 20% of all women experience, is one of the aging phenomena, and although there are individual differences, it begins slowly as the middle age passes.
여성갱년기란 내분비 증후군의 일종으로, 난소기능의 전반적이고 점진적인 노화로 인한 여성호르몬, 즉 에스트로겐(estrogen)의 감소로 인해 생리적 기능 및 성기능이 감소 내지 소실되는 과도기를 말한다. 에스트로겐은 여성의 자궁, 질, 골격근 및 심혈관계에서 이화작용 및 활성작용과 같은 필수적인 조절효과를 나타내는 것으로서(Couse and Korach, 1999; Korach et al., 1995), 적절한 배란, 난자의 수정, 임신뿐 아니라, 뼈 구조와 콜레스테롤 조절에 작용하는 것으로 알려져 있으며, 난소의 기능 평가에도 적용된다. Female menopause is a type of endocrine syndrome, and refers to a transition period in which physiological and sexual functions decrease or disappear due to a decrease in female hormones, that is, estrogen due to general and gradual aging of ovarian function. Estrogen exerts essential regulatory effects such as catabolic and active actions in the uterus, vagina, skeletal muscle, and cardiovascular system in women (Couse and Korach, 1999; Korach et al., 1995), as well as proper ovulation, fertilization of eggs, and pregnancy. However, it is known to act on bone structure and cholesterol regulation, and is also applied to the evaluation of ovarian function.
특히, 모든 여성의 경우 나이가 들면서 여성 특유의 갱년기 증상으로 인해 생활이 현저하게 불편해지고, 삶의 질이 크게 저하되는 현상을 겪게 된다. 여성 갱년기에 들어서면 특별한 이유도 없이 얼굴 화끈거림, 가슴 두근거림, 뼈와 근육의 통증, 수면장애, 성 불안감, 심한 기분변화, 불안과 우울감, 신경과민, 건망증, 자신감상실 등이 나타난다.In particular, in the case of all women, as they get older, their life becomes remarkably inconvenient and their quality of life is greatly reduced due to women's characteristic menopausal symptoms. When women enter menopause, for no particular reason, facial burning, chest palpitations, pain in bones and muscles, sleep disorders, sexual anxiety, severe mood changes, anxiety and depression, nervousness, forgetfulness, and loss of self-confidence appear.
이러한 증상을 갱년기 증상이라고 하는데, 이러한 갱년기의 구체적인 증상으로는 안면홍조, 빈맥, 발한 또는 두통과 같은 혈관성 변화에 의한 증상, 근육통, 관절통 및 요통과 같은 근골격계 변화에 의한 증상, 빈뇨 또는 요실금, 자궁과 질의 위축과 같은 비뇨생식기 변화에 의한 증상, 기억력 감퇴, 우울증, 집중력 감퇴 및 현기증과 같은 뇌신경계 변화에 의한 증상, 시력감퇴 및 피부와 모발의 변화와 같은 일반적인 증상들이 알려져 있다. These symptoms are called menopausal symptoms, and the specific symptoms of menopause include symptoms caused by vascular changes such as hot flashes, tachycardia, sweating or headache, symptoms caused by musculoskeletal changes such as muscle pain, arthralgia and back pain, frequent urination or incontinence, uterine and Symptoms due to changes in the genitourinary system such as vaginal atrophy, symptoms due to changes in the brain nervous system such as memory loss, depression, loss of concentration and dizziness, general symptoms such as loss of vision and changes in skin and hair are known.
이러한 갱년기의 여성에게는 생명 및 건강에 영향을 미치는 중요한 변화가 나타나게 되는데, 폐경 전후 여성의 대부분인 약 80%에서 갱년기 증상이 발생하고 의외로 장기간에 걸쳐 진행되는 경우가 많아서 여성의 건강에 치명적인 질환, 즉 골다공증이나 심혈관계 질환 등의 발생 위험성을 높이고 있다.In these menopausal women, important changes that affect life and health occur. Menopause symptoms occur in about 80% of women before and after menopause, and they often progress over a surprisingly long period of time, a disease fatal to women's health, that is, osteoporosis. It also increases the risk of developing cardiovascular diseases.
따라서 중년 여성들의 갱년기 증상으로 나타나는 신체적, 정신적 건강 및 삶의 질을 개선하기 위하여 갱년기 증상을 개선할 수 있는 치료법의 개발이 다수 연구되고 있다.Therefore, in order to improve the physical and mental health and quality of life that appear as symptoms of menopause in middle-aged women, a number of studies are being conducted on the development of treatments that can improve menopausal symptoms.
기존에 갱년기 증상을 개선할 수 있는 치료법의 예로는 호르몬 대체요법이나 비스테로이드계 제제 등의 약물을 사용한 약물요법이 있다. 그러나 에스트로겐 등의 호르몬을 사용한 대체요법의 경우 체내에 인위적인 호르몬 투여로 인한 거부반응과 자궁출혈, 뇌졸중, 심장발작, 유방암 및 자궁암의 발생 위험이 증가할 수 있는 것으로 알려져 있다(Swaran L., et al., Obstetrics & Gynecology, 91, 678-684, 1998). 또한, 비스테로이드계 제제 등 약물의 대부분이 두통, 체중증가 등의 부작용이 있는 것으로 알려져 있어서 새로운 문제가 되고 있다.Existing examples of treatments that can improve menopausal symptoms include drug therapy using drugs such as hormone replacement therapy or nonsteroidal agents. However, in the case of replacement therapy using hormones such as estrogen, it is known that the risk of rejection and uterine bleeding, stroke, heart attack, breast cancer and uterine cancer may increase due to artificial hormone administration in the body (Swaran L., et al. ., Obstetrics & Gynecology, 91, 678-684, 1998). In addition, since most of the drugs such as nonsteroidal drugs are known to have side effects such as headache and weight gain, it is a new problem.
이러한 문제점들을 개선하기 위해, 갱년기 증상 개선에 대한 다양한 연구가 이루어지고 있는데. 그 중 상당부분이 천연성분의 조성물을 이용한 기술이 제안되고 있다. 그 예로서, 한국특허공개 제10-2019-0113224호(황칠나무 발효 추출물 및 쥐눈이콩 발효 추출물을 포함하는, 여성 갱년기 질환 예방 및 치료용 약학적 조성물), 미국특허공개 제2011-0159123호(월경 전 증후군 완화용 조성물), 한국특허공개 제10-2011-0004603호(폐경기 질환의 치료 또는 예방, 피부 노화 방지, 또는 피부 주름 개선용 회화나무 추출물) 등이 제안되어 있다.In order to improve these problems, various studies are being made on the improvement of menopausal symptoms. Among them, a technology using a composition of natural ingredients has been proposed. As an example, Korean Patent Application Laid-Open No. 10-2019-0113224 (a pharmaceutical composition for preventing and treating female menopausal diseases, comprising a fermented extract of hwangchil tree and fermented soybean sprouts), US Patent Publication No. 2011-0159123 (menstruation) Composition for alleviating pre-syndrome), Korean Patent Laid-Open No. 10-2011-0004603 (Treatment or prevention of menopausal disease, prevention of skin aging, or an extract of cypress tree for improving skin wrinkles), etc. have been proposed.
그러나 이러한 종래기술들은 일부 폐경기 여성이나 여성 갱년기 증상 완화에 대한 방법을 제시하고 있지만, 그다지 뚜렷한 효과를 나타내지 못하고 있으며, 다양한 갱년기 증후군에 대한 극히 일부의 지엽적인 증상 호전을 기대하고 있을 뿐이다.However, although these prior arts suggest a method for relieving some menopausal women or women's menopausal symptoms, they do not show a very clear effect, and only a small portion of local symptom improvement for various menopausal syndromes is expected.
그러므로 여성 폐경 이후의 증후군이나 갱년기 증상 개선을 위한 해결에 대한 제품의 개발이 시급하고, 문제 해결이 충분하지 않은 단점이 있어서 그 상품화에 한계가 있었다.Therefore, there is an urgent need to develop a product to solve the post-menopausal syndrome or menopausal symptoms in women, and there is a limitation in commercialization because the problem is not sufficiently solved.
종래의 이와 같은 문제점을 개선하기 위해, 본 발명은 천연 성분을 이용하여 새로운 조성의 성분 구성으로 부작용이 없고 갱년기 증상 개선 등 다양한 면에서 건강증진에 효과가 있는 천연성분의 조성물의 제공을 해결과제로 한다.In order to improve such problems in the prior art, the present invention is to provide a composition of natural ingredients that is effective for health promotion in various aspects such as improvement of menopausal symptoms without side effects by using a new composition of ingredients using natural ingredients. do.
따라서 본 발명의 목적은 특정한 2 이상의 식물성 천연 복합성분을 함유하는 새로운 조성의 천연성분 조성물을 제공하는데 있다.Accordingly, an object of the present invention is to provide a natural component composition of a novel composition containing two or more specific vegetable natural complex components.
또한, 본 발명의 다른 목적은 특정 성분으로 이루어진 식물성 천연 복합성분을 함유하는 새로운 조성으로 갱년기 증상 개선의 효과를 가지는 새로운 용도의 조성물을 제공하는데 있다.In addition, another object of the present invention is to provide a composition for a new use having an effect of improving menopausal symptoms with a new composition containing a plant-natural complex component consisting of specific components.
또한, 본 발명의 또 다른 목적은 특정의 식물성 천연 복합성분을 함유하는 새로운 조성으로 안면홍조, 질 건강 및 질 pH 개선용의 효과를 가지는 새로운 용도의 건강식품을 제공하는데 있다.In addition, another object of the present invention is to provide a new use of health food having effects for improving facial flushing, vaginal health and vaginal pH with a new composition containing a specific plant natural complex component.
또한, 본 발명의 또 다른 목적은 특정의 식물성 천연 복합성분을 함유하는 새로운 조성으로 안면홍조, 질 건강 및 질 pH 개선, 갱년기 증상 개선의 효과를 가지는 새로운 용도의 약학적 조성물을 제공하는데 있다.In addition, another object of the present invention is to provide a new pharmaceutical composition containing a specific botanical natural complex component, which has the effect of improving facial flushing, vaginal health and vaginal pH, and improving menopausal symptoms.
또한, 본 발명의 또 다른 목적은 특정의 식물성 천연 복합성분을 함유하는 새로운 조성의 여성청결제를 제공하는데 있다.In addition, another object of the present invention is to provide a feminine cleanser of a new composition containing a specific plant natural complex component.
상기와 같은 과제 해결과 본 발명의 목적 달성을 위하여, 본 발명은 식물성 천연성분으로 회화나무, 순결나무 및 홉 중에서 선택된 어느 2성분 이상을 함유하는 것을 특징으로 하는 식물성 천연 복합성분 조성물을 제공한다.In order to solve the above problems and achieve the object of the present invention, the present invention provides a vegetable natural complex component composition comprising any two or more components selected from among pine trees, chastity trees and hops as a natural vegetable component.
본 발명의 바람직한 실시예에 따르면, 본 발명은 상기 식물성 천연 복합성분 조성물에는 추가적으로 차전자피, 프리바오틱스, 아연, 비타민 중에서 하나이상을 함유할 수 있다.According to a preferred embodiment of the present invention, the plant-natural complex component composition may additionally contain at least one of psyllium hull, prebiotics, zinc, and vitamins.
또한, 본 발명은 상기와 같은 식물성 천연 복합성분 조성물을 포함하는 건강증진용 조성물을 제공한다.In addition, the present invention provides a composition for health promotion comprising the natural plant-derived composition as described above.
또한, 본 발명은 상기와 같은 식물성 천연 복합성분 조성물을 포함하는 여성갱년기 증상 개선용 조성물을 제공한다.In addition, the present invention provides a composition for improving women's menopausal symptoms comprising the plant-based natural complex component composition as described above.
또한, 본 발명은 상기와 같은 식물성 천연 복합성분 조성물을 포함하는 안면홍조, 질 건강, 질 건조증 및 질 pH 개선용 조성물을 제공한다.In addition, the present invention provides a composition for improving facial flushing, vaginal health, vaginal dryness, and vaginal pH, including the vegetable natural complex composition as described above.
또한, 본 발명은 상기와 같은 식물성 천연 복합성분 조성물을 유효성분으로 포함하는 안면홍조, 질 건강, 질 건조증 및 질 pH 개선, 갱년기 증상 개선용 건강기능식품을 제공한다.In addition, the present invention provides a health functional food for improving facial flushing, vaginal health, vaginal dryness and vaginal pH, and improving menopausal symptoms, comprising the vegetable natural complex component composition as described above as an active ingredient.
또한, 본 발명은 상기와 같은 식물성 천연 복합성분 조성물을 유효성분으로 포함하는 안면홍조, 질 건강, 질 건조증 및 질 pH 개선, 갱년기 증상 개선용 약학적 조성물을 제공한다.In addition, the present invention provides a pharmaceutical composition for improving facial flushing, vaginal health, vaginal dryness and vaginal pH, and improving menopausal symptoms, comprising the vegetable natural complex component composition as described above as an active ingredient.
또한, 본 발명은 상기와 같은 식물성 천연 복합성분 조성물을 포함하는 여성청결제를 제공한다.In addition, the present invention provides a feminine cleanser comprising the plant natural complex component composition as described above.
본 발명에 따른 식물성 천연 복합성분은 특정한 2종이상의 식물성 천연성분을 혼합하여 복합성분 조성으로 구성함으로서 특히, 갱년기 증상의 개선 등에 현저한 효과를 나타내는 건강증진용 조성물로 유용하게 사용될 수 있다.The vegetable natural complex component according to the present invention is composed of a complex component composition by mixing specific two or more types of vegetable natural components, and in particular, it can be usefully used as a composition for health promotion that exhibits remarkable effects such as improvement of menopausal symptoms.
본 발명의 조성물은 특히 안면홍조, 질 건강, 질 건조증 및 질 pH 개선에 매우 우수한 효과를 나타낸다. In particular, the composition of the present invention exhibits a very good effect in improving hot flashes, vaginal health, vaginal dryness and vaginal pH.
특히, 본 발명의 조성물은 안면홍조, 질 건강 및 질 pH 개선 등을 포함하는 제방의 갱년기 증상의 개선에 효과가 있으며, 폐경기 증후군, 변비증상개선. 콜레스테롤 저감에 의한 혈행개선 등에도 효과가 있다. 또 이러한 조성물의 사용으로 인해 다른 건강이 저해되는 문제가 발생하지 않고 안전한 건강증진 효과를 유지할 수 있다는 점에서 기존의 일반적인 갱년기 증상 개선용 조성물이나 건강식품과는 다른 우수한 효과를 나타내는 것이다. 이것은 본 발명의 조성물에 대한 선택적인 혼합 구성으로 인해 나타나는 상승효과에 기인한 것으로 보인다.In particular, the composition of the present invention is effective in improving menopausal symptoms of the embankment, including hot flashes, vaginal health and vaginal pH improvement, and improvement of menopausal syndrome and constipation symptoms. It is also effective in improving blood circulation by reducing cholesterol. In addition, the use of such a composition does not cause other health problems and can maintain a safe health-promoting effect, which shows an excellent effect different from the conventional composition for improving general menopausal symptoms or health food. This appears to be due to the synergistic effect exhibited by the selective mixing configuration for the composition of the present invention.
또한, 본 발명의 조성물은 상기와 같은 다양한 효과를 나타내는 건강증진용 건강보조식품 외에도, 건강기능식품 또는 약학적 조성물로 바람직하게 이용될 수 있다.In addition, the composition of the present invention can be preferably used as a health functional food or a pharmaceutical composition, in addition to a health supplement for health promotion exhibiting various effects as described above.
이하, 본 발명을 하나의 구현예로서 더욱 상세하게 설명하면 다음과 같다.Hereinafter, the present invention will be described in more detail as one embodiment as follows.
본 발명은 특정한 2종 이상의 식물성 천연성분을 혼합하여 이루어지는 조성물과 이를 이용하여 제조되는 건강식품에 관한 것으로서, 하기 설명하는 구현예들은 본 발명을 상세히 설명하기 위한 하나의 참조일 뿐 본 발명이 이에 한정되는 것은 아니며, 여러 형태로 구현될 수 있다.The present invention relates to a composition made by mixing two or more specific vegetable natural ingredients and a health food prepared using the same, and the embodiments described below are only a reference for explaining the present invention in detail, and the present invention is limited thereto It is not, and may be implemented in various forms.
본 발명에서 선택적으로 적용하는 특정한 식물성 천연성분인 회화나무, 순결나무, 홉 중에서 선택된 하나 이상의 성분의 특정 조성과 혼합된 것을 유효성분으로 하는 건강증진용 조성물은 제안되어 있지 않다.A composition for health promotion using as an active ingredient a mixture of one or more components selected from among the specific botanical natural ingredients selectively applied in the present invention, such as chrysanthemum, chrysanthemum, and hops, as an active ingredient has not been proposed.
특히, 본 발명의 조성물은 회화나무, 순결나무, 홉 중에서 선택된 2성분 이상이 혼합된 상태로서, 이들의 혼합물이 상승효과를 일으켜 인체에 매우 유익한 환경을 조성하도록 하는 효과를 발휘한다.In particular, the composition of the present invention exhibits the effect of creating an environment that is very beneficial to the human body by generating a synergistic effect of the composition in a state in which two or more components selected from among woody figs, chastity wood, and hops are mixed.
이는 기존에 회화나무, 순결나무 또는 홉이 단독으로 사용된 경우에 비해 월등하게 우수한 효과를 발휘한다.This exhibits a significantly superior effect compared to the case in which pine wood, chastity wood, or hops were used alone.
본 발명의 바람직한 실시예에 의하면, 상기 3성분 중에서 2성분이 혼합되는 경우는 제1성분 10-90중량%와 제2성분 10-90중량%로, 더욱 바람직하게는 제1성분 20-80중량%와 제2성분 20-80중량%로, 다른 예로서는 각각 30-70중량%, 또 다른 예로서는 각각 40-60중량%로 함유될 수 있다.According to a preferred embodiment of the present invention, when two components are mixed among the three components, 10-90% by weight of the first component and 10-90% by weight of the second component, more preferably 20-80% by weight of the first component % and 20-80% by weight of the second component, as another example, each 30-70% by weight, and as another example, each may be contained in an amount of 40-60% by weight.
상기 3성분인 회화나무, 순결나무 및 홉이 모두 혼합되는 경우는 (10-90) : (10-90) : (10-90)중량부, 다른 예로서는 각각 20-80중량부, 각각 30-70중량부, 또 다른 예로서는 각각 40-60중량부로 혼합하여 함유될 수 있다.When all of the three components, cypress wood, chaste wood, and hops are mixed, (10-90): (10-90): (10-90) parts by weight, as another example, each 20-80 parts by weight, each 30-70 parts by weight Parts by weight, as another example, each may be contained by mixing 40-60 parts by weight.
본 발명의 바람직한 실시예에 의하면, 상기와 같은 천연성분의 추출물 제조를 위해 사용되는 추출 용매는 예컨대, 물, 탄소수 1 내지 4의 알코올, 에틸아세테이트, 헥산, 디클로로메탄, 아세폰, 클로로포름, 메틸렌 클로라이드중에서 하나이상의 용매로 추출할 수 있다. 더욱 바람직하게는 에탄올 수용액을 사용하여 분쇄물의 중량비로 3 내지 10배에 상응하는 추출 용매를 첨가하고, 상온에서 추출할 수 있다. 예컨대, 상기 추출은 바람직하게는 6 내지 24시간 추출하는 것이 바람직하다. 이러한 용매를 이용하여 추출한 이후에는 여과한 다음, 여액을 원심분리시켜 침전물을 제거하고, 감압 농축 또는 농축한 후, 동결 건조할 수 있다. According to a preferred embodiment of the present invention, the extraction solvent used for preparing the extract of the natural component as described above is, for example, water, alcohol having 1 to 4 carbon atoms, ethyl acetate, hexane, dichloromethane, acetone, chloroform, methylene chloride It can be extracted with one or more solvents. More preferably, an extraction solvent corresponding to 3 to 10 times the weight ratio of the pulverized product may be added using an aqueous ethanol solution, and extraction may be performed at room temperature. For example, the extraction is preferably performed for 6 to 24 hours. After extraction using such a solvent, it may be filtered, and the filtrate may be centrifuged to remove a precipitate, concentrated under reduced pressure or concentrated, and then freeze-dried.
본 발명의 바람직한 구현예에 의하면, 본 발명에서 사용되는 식물성 천연성분은 서로 구별하여 별도 분리된 상태로 함유될 수 있다.According to a preferred embodiment of the present invention, the vegetable natural ingredients used in the present invention may be contained in a separate state to distinguish them from each other.
예컨대, 본 발명의 일 실시예의 구성으로서, 각 성분들은 서로 별도의 미세 캡슐화된 형태로 사용될 수 있다.For example, as a configuration of an embodiment of the present invention, each component may be used in separate microencapsulated form.
또 다른 예로서는, 투명한 캡슐 내에 각각의 식물성 천연성분이 분할된 상태 또는 이중 캡슐 형태로 혼합될 수 있다. As another example, each vegetable natural ingredient may be mixed in a divided state or in a double capsule form in a transparent capsule.
본 발명의 조성물은 추가적으로 프리바이오틱스, 아연, 비타민 중에서 하나 이상을 함유할 수 있다. 이러한 추가성분이 혼합되는 경우 전체 조성물에 대하여 이러한 추가성분이 0.1-40중량%, 통상적으로는 1-30중량%로 함유될 수 있다.The composition of the present invention may additionally contain one or more of prebiotics, zinc, and vitamins. When these additional components are mixed, the amount of these additional components may be 0.1-40% by weight, typically 1-30% by weight based on the total composition.
또한, 본 발명의 조성물은 추가적으로 아티초크추출물, 치커리뿌리추출물, 베리류, 검정콩분말, 알로에분말, 조류분말, 핑거루트, 난소화성말토덱스트린, 스테비아분말, 탈지분유, 알로에아보레센스, 홍삼 중에서 선택된 하나이상을 함유할 수 있다. 이러한 추가 성분도 전체 조성에 대해 1-30중량%로 함유할 수 있다.In addition, the composition of the present invention may additionally contain at least one selected from artichoke extract, chicory root extract, berries, black bean powder, aloe powder, algae powder, finger root, indigestible maltodextrin, stevia powder, skim milk, aloe borescens, and red ginseng. may contain. These additional components may also be contained in an amount of 1-30% by weight based on the total composition.
본 발명의 바람직한 일 실시예에 따르면, 상기 조성물에서 하나의 바람직한 구성예로서는 회화나무, 순결나무 및 홉 중에서 선택된 2이상의 천연성분 60-90중량%, 프리바이오틱스 1-35중량%. 아연 0.1-3중량%, 비타민 0.1-3중량% 로 함유된 조성물로 구성될 수 있다. According to a preferred embodiment of the present invention, as one preferred constituent example in the composition, 60-90% by weight of two or more natural ingredients selected from cypress wood, chastity wood and hops, 1-35% by weight of prebiotics. It may be composed of a composition containing 0.1-3% by weight of zinc and 0.1-3% by weight of vitamins.
본 발명에서 사용되는 회화나무는 이소플라본이 풍부하게 들어있어 생리활성 기능이 뛰어나 갱년기 증상 개선 등의 건강에 도움을 줄 수 있다. 꽃과 열매에 함유된 루틴(rutin)과 베투린(Betulin) 성분은 고혈압, 콜레스테롤 저하 등 심혈관 질환 연구가 활발하게 진행되고 있으며, 한방에서는 지혈, 구충작용, 진정, 토혈 및 피부병 치료에 쓴다. 회화나무 열매가 갱년기에 탁월한 효과가 있는 이유는 이소플라본이 풍부하기 때문인데, 이소플라본은 여성 호르몬인 에스트로겐과 분자구조뿐만 아니라 효능까지도 유사하다. 그래서 우리 몸에 에스트로겐이 부족할 경우 에스트로겐 분비를 유도하거나 그 역할을 대신하기도 한다.The fig tree used in the present invention is rich in isoflavones, so it has excellent physiological activity and can help health such as improvement of menopausal symptoms. Rutin and Betulin, which are contained in flowers and fruits, are being actively studied for cardiovascular diseases such as high blood pressure and cholesterol lowering. The reason that the fruit of the sycamore tree has an excellent effect on menopause is because it is rich in isoflavones, which are similar to estrogen, a female hormone, in molecular structure as well as in efficacy. Therefore, when estrogen is insufficient in our body, it induces the secretion of estrogen or takes its place.
또한, 본 발명에서 사용되는 순결나무는 플라보노이드 성분과 이리도이드 성분이 함유되어 있어 호르몬 기능 정상화 및 여성 생리불순, 내분비 개선 등 갱년기 개선 등 전반적인 성인병 건강에 도움을 줄 수 있다. 특히, 월경전증후군(PMS)으로 인한 두통, 피부증상, 가슴팽창, 아랫배 통증, 신경과민, 과민성 감정굴곡, 짜증스러움, 우울, 피로, 수면장애 등의 신체적 및 정신적 증상의 치료, 월경불순 개선 등 갱년기 증상 개선에 효과를 나타낸다.In addition, the chastity tree used in the present invention contains flavonoid components and iridoid components, so it can help normalize hormone function and improve overall health of adult diseases, such as improvement of menstruation, such as female menstrual irregularities and endocrine improvement. In particular, treatment of physical and mental symptoms such as headache, skin symptoms, chest distension, abdominal pain, irritability, irritability, bending of emotions, irritability, depression, fatigue, and sleep disturbance caused by PMS, improvement of menstrual irregularities, etc. It is effective in improving menopausal symptoms.
순결나무의 열매인 체이스트 트리 베리(Chaste tree berry)는 과실에는 flavonoid로 vitexin과 casticin, iridoid 성분으로 agnuside(아그너사이드)와 aucubin(어쿠빈) 등이 함유되어 있고, 주 구성성분이 caryophyllene oxide(25%), n-hexadecane(12.5%), α-terpinyl actate(11.6%), bicyclogermacrene (8.4%)으로 확인되었다. 특히, 본 발명에 따르면, 순결나무 열매 추출물 섭취군은 학습 및 기억능이 개선되고 에스트로겐 수용체의 발현이 증가한다.The chaste tree berry, the fruit of the chastity tree, contains vitexin and casticin as flavonoids, and agnuside and aucubin as iridoid components, and the main component is caryophyllene oxide. (25%), n-hexadecane (12.5%), α-terpinyl actate (11.6%), and bicyclogermacrene (8.4%) were identified. In particular, according to the present invention, the group taking the extract of chrysanthemum fruit extract improved learning and memory and increased the expression of estrogen receptors.
본 발명에 사용되는 홉은 prenylflavonoid로 8-prenylnaringenin(프레닐나린제닌)과 isoxanthohumol이 함유되어 있으며 이중 8-prenylnaringenin은 강력한 식물성 에스트로겐 활성을 나타낸다. 홉 100g 중에 30.000-300.000IE(IU)의 estrogen이 함유되어 있다. 그러므로 갱년기 때 나타날 수 있는 홍조증상, 골다공증 등 여러 갱년기 증상들을 완화시키는데 도움을 줄 수 있다. 또한, 소화불량, 변비, 복부팽만 등 소화기관에 도움이 되고 정신적으로는 숙면, 불면증 치유, 스트레스 완화, 불안감 상쇄에 도움을 줄 수 있다.Hops used in the present invention are prenylflavonoids and contain 8-prenylnaringenin (prenylnaringenin) and isoxanthohumol, of which 8-prenylnaringenin exhibits strong phytoestrogenic activity. 100g of hops contains 30.000-300.000 IE (IU) of estrogen. Therefore, it can help relieve various menopausal symptoms such as hot flashes and osteoporosis that may appear during menopause. In addition, it is helpful for digestive organs such as indigestion, constipation, and abdominal distension, and mentally it can help to sleep well, heal insomnia, relieve stress, and offset anxiety.
본 발명에서 사용 가능한 프리바오틱스로서는 다양한 성분이 사용가능하다, 예컨대 바람직하게는 포도당, 구연산, 에리스리톨, 프락토올리고당, 말토오스, 글루코만난, 자이리톨 중에서 하나이상이 사용될 수 있다.As the prebiotics usable in the present invention, various components can be used, for example, preferably, one or more of glucose, citric acid, erythritol, fructooligosaccharide, maltose, glucomannan, and xylitol can be used.
본 발명에서 사용되는 비타민 성분으로는 비타민 C, 비타민 B 군 등이 사용될 수 있다. 여기서 사용될 수 있는 비타민 B 군으로서 비타민 B1은 탄수화물 대사에서 transketolase, pyruvate dehydrogenase, 
또한, 비타민 B2는 장점막 세포에서 FAD(flavin adenine dinucleotide) 상태로 변화하여 산화, 환원반응을 촉진하는 flavoenzyme의 조효소로 사용되며 수소 운반 역할을 담당하며 성장과 세포의 재생을 도와 건강한 피부, 모발, 손톱, 발톱을 만들어 주는 데 기여하므로 성인병 예방과 활력 증진으로 갱년기 극복에 도움이 된다. In addition, vitamin B2 is used as a coenzyme of flavoenzyme that promotes oxidation and reduction reactions by changing to FAD (flavin adenine dinucleotide) state in intestinal mucosa cells. , it contributes to making toenails, so it helps to overcome menopause by preventing adult diseases and enhancing vitality.
그리고 비타민 B6는 단백질 대사에 관여하여 건강한 피부와 점막, 모발 성장을 촉진하며, 뇌기능 향상에 도움을 주고 뇌가 수축하는 속도를 감소시켜 치매 위험을 낮춰주며 에스트로겐의 대사에 관여해 호르몬 밸런스를 맞춰 주어 월경전 증후군의 증상을 완화하는데 효과가 있다.In addition, vitamin B6 is involved in protein metabolism to promote healthy skin, mucous membrane and hair growth, helps to improve brain function, reduces the rate of brain contraction, lowers the risk of dementia, and is involved in estrogen metabolism to balance hormones. It is effective in alleviating the symptoms of premenstrual syndrome.
본 발명에서 사용가능한 아연은 주요 효소 및 전사인자를 포함하는 300여 종 이상 단백질의 zinc finger motif에 결합 후 보조인자로 작용하여 면역반응 조절에 기여한다.Zinc usable in the present invention contributes to the regulation of immune responses by binding to zinc finger motifs of more than 300 proteins including major enzymes and transcription factors and acting as a cofactor.
상기와 같이, 본 발명의 구성은 프로바이오틱스와 특정 식물성 천연성분을 함유하는 조성물로서 건강식품으로서 유용한데, 특히 장 건강과 갱년기 증상 개선에 효과가 우수한 것으로 나타났다. 구체적으로는 여성 갱년기 증상 개선으로서, 특히 안면홍조, 질 건조증, 질 pH 개선 등에 우수한 효과가 있고, 장 건강 개선으로 변비개선, 다이어트, 콜레스테롤 감소, 혈행개선 등에 효과가 우수한 것으로 확인되었다. 이러한 본 발명의 효과는 기존에 단순한 갱년기 증상 개선 효과에 비해 월등하게 우수한 상승효과가 있는 것으로 나타났다. As described above, the composition of the present invention is useful as a health food as a composition containing probiotics and specific vegetable natural ingredients, and it was found to be particularly effective in improving intestinal health and menopausal symptoms. Specifically, it was confirmed that it has excellent effects in improving women's menopausal symptoms, particularly hot flushes, vaginal dryness, and vaginal pH improvement. The effect of the present invention was found to have a significantly superior synergistic effect compared to the conventional simple menopausal symptom improvement effect.
또한, 본 발명의 조성물은 무엇보다도 일부 갱년기 증상이 개선되더라도 다른 부분에서 건강이 더 나빠지는 경우가 발생하지 않는다는 점에서 바람직하다.In addition, the composition of the present invention is preferable in that, above all, even if some menopausal symptoms are improved, health does not deteriorate in other parts.
특히, 여성갱년기 증상 중에서 특히 안면홍조, 질 건조증, 질 건강, 질 pH 개선에 특히 우수한 효과가 있는 것 이외에도, 골다공증, 가슴 울렁거림, 빈맥, 발한, 두통, 근육통, 관절통, 요통, 빈뇨, 요실금, 자궁과 질의 위축, 기억력 감퇴, 우울증, 집중력 감퇴, 현기증, 건망증, 시력감퇴, 피부와 모발의 변화, 짜증스러움, 피로, 수면장애, 월경전 증후군, 폐경증후군 등에 대해서도 우수한 효과를 나타낸다.In particular, among the symptoms of menopause, in addition to being particularly effective in improving hot flashes, vaginal dryness, vaginal health, and vaginal pH, osteoporosis, heartburn, tachycardia, sweating, headache, muscle pain, arthralgia, back pain, frequent urination, urinary incontinence, It has excellent effects on uterine and vaginal atrophy, memory loss, depression, loss of concentration, dizziness, forgetfulness, loss of vision, skin and hair changes, irritability, fatigue, sleep disturbance, premenstrual syndrome, and menopause syndrome.
그러므로 본 발명은 바람직하게도, 상기와 같은 조성물을 함유하는 여성갱년기 증상 개선용 조성물을 제공한다.Therefore, the present invention preferably provides a composition for improving female menopausal symptoms containing the composition as described above.
또한, 본 발명은 상기와 같은 조성물을 함유하는 안면홍조, 질 건조증, 질 건강, 질 pH 개선용 건강식품으로 적용될 수 있다. 바람직하게는 건강보조식품이나 건강기능식품으로 적용될 수 있다.In addition, the present invention can be applied as a health food for improving facial flushing, vaginal dryness, vaginal health, and vaginal pH containing the above composition. Preferably, it can be applied as a health supplement or health functional food.
또한, 본 발명의 바람직한 구현예로서는 이러한 조성물의 건강식품은 피부미용 개선의 효과도 있어서 이너뷰티 개념의 화장료 조성물도 포함하는 것으로 해석될 수 있다.In addition, as a preferred embodiment of the present invention, the health food of such a composition also has the effect of improving skin beauty, so it can be interpreted as including a cosmetic composition of the concept of inner beauty.
또한, 본 발명은 상기와 같은 조성물을 함유하는 안면홍조, 질 건조증, 질 건강, 질 pH 개선 및 갱년기 증상 치료용 약학적 조성물을 포함한다.In addition, the present invention includes a pharmaceutical composition for treating hot flashes, vaginal dryness, vaginal health, vaginal pH improvement and menopausal symptoms containing the composition as described above.
또한, 본 발명은 상기와 같은 조성물을 함유하는 여성청결제로 제조하여 사용할 수 있다.In addition, the present invention can be prepared and used as a feminine cleanser containing the composition as described above.
본 발명에 따른 조성물은 건강식품이나 약제학적 조성물로 투여하기 위해 일반적으로 분말, 엑기스, 그래뉼, 겔상, 입상, 펠릿형, 환형, 캡슐제, 정제 등의 제형으로 제조가 가능하다. 이러한 제형은 본 발명의 조성물을 그대로 이용하거나 다른 천연 첨가제 등을 혼합하여 제조할 수 있다.The composition according to the present invention can be generally prepared in the form of powder, extract, granule, gel, granular, pellet, round, capsule, tablet, etc. for administration as a health food or pharmaceutical composition. Such a formulation can be prepared by using the composition of the present invention as it is or by mixing other natural additives.
이러한 본 발명에 따른 조성물을 이용하는 건강식품이나 약학적 조성물은 통상적인 경구제형으로 투여할 수 있다.The health food or pharmaceutical composition using the composition according to the present invention can be administered in a conventional oral dosage form.
이러한 제형으로는 액제, 고형제 등으로 경구투여 가능하고, 피부 외용제로도 적용이 가능하다. 액제로는 샷(Shot), 엑기스, 드링크제 등으로 제조할 수 있고, 고형제로는 분말, 그래뉼, 캡슐제, 정제 등으로 제조할 수 있다. 피부외용제의 예로서 전형적으로는 화장료나 여성청결제로 제조하여 사용하는 경우 우수한 효과를 기대할 수 있다.These formulations can be administered orally in a liquid or solid form, and can also be applied as an external preparation for skin. Liquid formulations may be prepared as shots, extracts, drinks, and the like, and solid formulations may be prepared as powders, granules, capsules, tablets, and the like. As an example of an external preparation for skin, excellent effects can be expected when it is typically prepared and used as a cosmetic or feminine cleanser.
이러한 본 발명에 따른 조성물의 제형은 예컨대 10-1,000mg/정, 1-10g/포 등의 제형으로 1일 1-3회 섭취할 수 있다.The formulation of the composition according to the present invention may be ingested 1-3 times a day, for example, in a formulation such as 10-1,000 mg/tablet, 1-10 g/pack.
이상에서 설명한 바와 같은 본 발명은 하기의 실시예에 의하여 더욱 자세하게 설명하겠는바, 본 발명이 다음 실시예에 의하여 한정되는 것은 아니다.The present invention as described above will be described in more detail by the following examples, but the present invention is not limited by the following examples.
실시예 1 - 6, 비교예 1-3 : 조성물의 제조Examples 1-6, Comparative Examples 1-3: Preparation of compositions
회화나무 열매추출물, 순결나무 열매추출물 또는 홉 추출물 등을 하기 조성비율(중량%)로 사용하여 천연성분 조성물로서 하기 표 1의 조성에 따라 분말을 제조하였다. A powder was prepared according to the composition of Table 1 below as a natural component composition by using the fruit extract of the sycamore tree, the fruit extract of the chrysanthemum tree, or the hop extract in the following composition ratio (% by weight).
또한, 다른 예로서는 하기 표 1에 나타낸 바와 같은 성분을 해당 함량 비율로 혼합하여 천연성분 조성물을 각각 제조하였다.In addition, as another example, ingredients as shown in Table 1 were mixed in the corresponding content ratio to prepare natural ingredient compositions, respectively.
(2) 알로에로는 알로에아보레센스를 사용함
(3) 유산균으로는 락도바실러스 혼합균을 사용함
(4) 프리바이오틱스로서는 포도당, 자일리톨, 구연산 혼합물을 사용함
(5) 비타민으로서는 비타민 C, 비타민 B1, B2, B6의 혼합성분을 사용함
(6) 비교예4의 경우는 회화나무의 유산균(락토바실러스 플란타쿰) 발효물을 사용함(1) Dextrin uses indigestible maltodextrin
(2) Aloe vera is used.
(3) Lactobacillus mixed bacteria are used as lactic acid bacteria
(4) A mixture of glucose, xylitol and citric acid is used as prebiotics
(5) Vitamin C, vitamin B1, B2, B6 mixed ingredients are used as vitamins.
(6) In the case of Comparative Example 4, a fermented product of lactic acid bacteria (Lactobacillus plantacum) of the sapling tree was used
실험예 1 : 혈액 중의 17β-estradiol의 농도 측정 Experimental Example 1: Measurement of the concentration of 17β-estradiol in blood
21일령의 Sprague Dawley 암컷 흰쥐를 각 군당 5마리씩(평균체중 50g) 준비하고 6개월령의 흰쥐 역시 각 군당 5마리씩(평균체중 350g) 준비하여 상기 실시예, 비교예에 따라 제조된 시료를 100mg/kg body wt/day씩 3일간 경구 투여하였다. 시료 투여 전 혈액과 3 일간 경구 투여한 후 EIA(Enzyme Immuno Assay)를 이용하여 혈액 중 17β-에스트라디올의 농도를 측정하였다. 그 결과를 하기 표 2에 나타내었다.21-day-old female Sprague Dawley rats were prepared in each group by 5 mice (average weight 50 g), and 6-month-old rats were also prepared in each group by 5 mice (average weight 350 g). Samples prepared according to the Examples and Comparative Examples were 100 mg/kg Body wt/day was orally administered for 3 days. The concentration of 17β-estradiol in the blood was measured by using EIA (Enzyme Immuno Assay) after oral administration with blood before sample administration for 3 days. The results are shown in Table 2 below.
(pg/ml)Concentration of 17β-estradiol
(pg/ml)
암컷21 days
female
암컷6 months
female
상기 표 2로부터, 실시예의 조성물을 투여한 경우 미성숙 쥐와 성숙 쥐 모두 여성 호르몬인 에스트라디올의 농도가 다른 경우에 비해 크게 증가하는 것으로 나타났다. From Table 2, it was found that the concentration of estradiol, a female hormone, was significantly increased in both immature and mature mice when the composition of Example was administered compared to the other cases.
따라서 위 실험결과로부터, 실시예의 조성물은 비교예에 비해 에스트라디올의 분비 감소에 기인하는 여성갱년기 증상을 현저하게 개선할 수 있다는 것을 확인할 수 있다.Therefore, from the above experimental results, it can be confirmed that the composition of Examples can remarkably improve the symptoms of gynecomastia caused by decreased secretion of estradiol compared to Comparative Examples.
실험예 2 : 난소절제 암컷 랫트를 이용한 폐경 동물 모델에서의 갱년기 증상 개선 효과Experimental Example 2: Effect of improving menopausal symptoms in an animal model of menopause using ovariectomized female rats
(1) 난소절제 동물 모델의 준비(1) Preparation of ovariectomized animal models
실험은 생후 7~8주령의 SD 암컷 랫트를 구입하여 일정한 온도(23±1℃)와 습도(50±5%)하에서 1주일간 적응시킨 후 인체 폐경을 모방한 갱년기 증상 유발 모델을 만들기 위해 마취 하에서 양쪽 난소 절제 수술을 실시하였고 대 조군에는 난소는 그대로 둔 채, 모의수술만 실시한 후 3주간 회복기를 두었다.The experiment was conducted under anesthesia to create a model for inducing menopausal symptoms imitating human menopause after purchasing 7-8 week old SD female rats and acclimatizing them for 1 week under constant temperature (23±1℃) and humidity (50±5%). Resection of both ovaries was performed. In the control group, the ovaries were left as they were, and only the simulation operation was performed, followed by a 3-week recovery period.
(2) 시험군 선정 및 시료 처리(2) Test group selection and sample processing
실험군은 모의수술군, 난소절제군, E2 투여군 및 시료 투여군 등 총 4군으로 구성하고, 모의수술군과 난소절제 대조군에는 0.5% CMC (carboxymethylcellulose) 용액을, E2 투여군에는 17β-에스트라디올(0.25mg/kg/day)을, 시료 투여군에는 시료 조성물을 랫트 체중 kg 당 40 mg의 농도로 12주간 경구투여 하였다. 랫트에 투여한 40 mg/kg의 용량은 중년 여성을 기준으로 1일 섭취량 환산하면 약 270 mg의 섭취수준에 해당된다.The experimental group consisted of a total of 4 groups: a simulated surgery group, ovariectomy group, E2 administration group, and sample administration group. 0.5% CMC (carboxymethylcellulose) solution was administered to the simulated surgery group and ovariectomy control group, and 17β-estradiol (0.25 mg) was administered to the E2 administration group. /kg/day), the sample composition was orally administered to the sample administration group at a concentration of 40 mg per kg of rat body weight for 12 weeks. A dose of 40 mg/kg administered to rats corresponds to an intake level of about 270 mg in terms of daily intake for middle-aged women.
(3) 꼬리피부온도 평가 (3) Tail skin temperature evaluation
12주간 조성물 섭취 후 갱년기의 대표증상인 안면홍조의 지표로서 랫트의 꼬리피부온도를 측정하였다. 랫트를 고정대에 고정하고 안정시킨 후 적외선 온도측정기(Bioseb)를 이용하여 총 5회 측정하여 그 평균값으로 꼬리피부온도를 결정하였다. 그 결과는 하기 표 3에서 나타낸 바와 같다.After 12 weeks of ingestion of the composition, the tail skin temperature of rats was measured as an indicator of hot flashes, a representative symptom of menopause. After the rat was fixed on the fixture and stabilized, it was measured a total of 5 times using an infrared thermometer (Bioseb), and the tail skin temperature was determined with the average value. The results are as shown in Table 3 below.
상기 표에서 보면, 시료 투여군 중 실시예 조성물의 투여군의 경우 다른 군에 비해 난소절제로 인해 상승되었던 꼬리피부온도를 매우 큰 차이로 감소시켰다(P<0.05). Referring to the table above, among the sample administration groups, the administration group of the Example composition reduced the tail skin temperature, which had been raised due to ovariectomy, by a very large difference compared to the other groups (P<0.05).
특히, 이 실험결과로부터 실시예의 조성물이 비교예의 조성물에 비해 갱년기의 증상인 안면홍조 증상을 현저하게 개선시키는 효과가 있다는 사실도 확인되었다.In particular, from this experimental result, it was also confirmed that the composition of Examples has an effect of remarkably improving the hot flashes, a symptom of menopause, compared to the composition of Comparative Examples.
실험예 3 ; 질 건강 확인실험Experimental Example 3; vaginal health test
질 건강에 대한 확인 실험을 위해 50-65세 여성 중에서 갱년기 증상을 보이는 21명의 여성을 피험자로 선정하여 질 건강 증상으로 질 건조, 통증, 냄새, 느낌, 민감성, 각질 생성 여부 등 상황에 대하여 1개월(평균 주 1회) 간 자가 측정하고 종합 결과를 평가하도록 하였다. 피험자 중에서 2명(A그룹)은 출산 경험이 없는 미혼자이고 나머지 10명(B그룹)은 기혼자로서 출산 경험이 있는 여성으로 포함시켰다.For vaginal health confirmation experiment, 21 women with menopausal symptoms among 50-65 years old women were selected as subjects, and vaginal health symptoms such as vaginal dryness, pain, smell, feeling, sensitivity, and keratin production were evaluated for 1 month. The liver was self-measured (on average once a week) and the overall results were evaluated. Among the subjects, 2 (Group A) were single, and the remaining 10 (Group B) were married women who had childbirth.
실험은 A, B 그룹 모두에게 시료를 2개월간 1일 2회 복용하고, 복용전과 복용 2개월 후 상태를 확인하는 방식으로 진행하였다.The experiment was conducted in a way that both groups A and B took the sample twice a day for 2 months, and checked the status before and 2 months after taking the sample.
피험자를 (가)군 12명, (나)군 9명으로 나누어서 (가)군에게는 각기 시료로서 실시예 1, 2, 3, 4를 (나)군에게는 비교예 1, 2, 3을 각각 2명씩 사용하도록 하였다.The subjects were divided into 12 participants in group (A) and 9 participants in group (B), and each sample was given Examples 1, 2, 3, and 4 for group (A) and Comparative Examples 1, 2, and 3 for group (B), respectively. were used by each person.
측정은 해당 시료에 대해 질 건조감(변화나 개선), 통증(여부), 기타 등 2가지와, 전체적인 질 환경의 개선 느낌 등의 평가 방식으로 평가하였다.Measurements were evaluated in two ways, such as vaginal dryness (change or improvement), pain (whether or not), and others, and the overall feeling of improvement in the vaginal environment for the sample.
평가점수는 1 내지 10으로 하고, 평가 결과가 우수한 것은 10, 품질이 나쁜 것을 1로 평가하고, 평가점수는 피험자의 모든 평가점수를 합하고 1인 평균 수치를 구한 후 계산된 수치를 최종 결과로 하고, 그 최종 측정 결과를 다음 표 4에 정리하였다.The evaluation score is set to 1 to 10, the excellent evaluation result is evaluated as 10, and the poor quality is evaluated as 1, and the evaluation score is the final result after adding up all evaluation scores of the subject and obtaining the average value of 1. , the final measurement results are summarized in Table 4 below.
실험예 4 : 장 건강 실험Experimental Example 4: intestinal health experiment
상기 실시예와 비교예에 따른 각 시료에 대하여 대장관내 점액질의 분비에 미치는 효과를 측정하여, 변비 효과와 관련된 장기능 개선 효과를 알아보기 위해 대장관내 점액질분비에 대한 효과를 조사하였다.For each sample according to Examples and Comparative Examples, the effect on the secretion of mucus in the colon was measured, and the effect on the secretion of mucus in the colon was investigated in order to examine the effect of improving intestinal function related to the effect of constipation.
소화기관의 점액질은 기계적인 손상과 화학적인 자극으로부터 상피조직인 장내 표면을 보호하는 역할과 소화운동의 윤활제 역할을 한다. 장 점막 (colonic mucosa)은 점액질 (Mucus)로 덮혀 있으며, 점액소(Mucin)는 점액질의 물리적, 화학적 특성을 나타내는 가장 중요한 역할을 하는 것으로 알칼리성에서 점성질의 액이 된다. 변비증상이 있을 경우에는 장 점막에서 점막층의 기능이 감소되며, 로페라마이드를 일정기간 투여하면 대장관의 점액질의 두께가 얇아져서 대장 내용물의 이동에 지장을 초래하게 된다.The mucus of the digestive system protects the intestinal surface, which is an epithelial tissue, from mechanical damage and chemical stimuli, and acts as a lubricant for digestion. The intestinal mucosa (colonic mucosa) is covered with mucus, and mucin plays the most important role in showing the physical and chemical properties of the mucus, and it becomes a viscous liquid from alkaline. In the case of constipation, the function of the mucosal layer in the intestinal mucosa is reduced, and if loperamide is administered for a certain period of time, the thickness of the mucus in the large intestine becomes thin, which interferes with the movement of the contents of the large intestine.
실험을 위한 처리는 동물모델로 웅성의 평균 체중 220-240g 정도의 스프라그 도울리(Sprague Dawley) 랫트 (대한바이오링크, 음성)를 1군당 8 내지 10 마리를 사용하여 대사 케이지에서 3일간 순화 적응시키고, 4일째부터 변비를 유발시키기 위해 로페라마이드 (Sigma사, 미국)를 사료 3g당 1mg 함유하는 사료를 공급하였다. The treatment for the experiment is an animal model using 8 to 10 male Sprague Dawley rats (Daehan Biolink, Negative) with an average male weight of 220-240 g per group and acclimatized in a metabolic cage for 3 days. In order to induce constipation from the 4th day, a feed containing 1 mg of loperamide (Sigma, USA) per 3 g of feed was supplied.
실험동물의 맹장에서 직장까지를 적출하여 10% 포름알데하이드 인산염 완충용액에 고정시켜 대장관내 있는 변(feces pellet)의 갯수를 육안으로 관찰하였다.The number of feces pellets in the large intestine was visually observed by removing the cecum from the rectum of the experimental animals and fixing them in 10% formaldehyde phosphate buffer solution.
그 실험 결과는 다음 표 5에 나타내었다.The experimental results are shown in Table 5 below.
상기 실험 결과, 대조군에서는 평균 변의 갯수가 5.0개였으며, 이에 비해 실시예의 경우 상당부분 감소된 1.80-2.00개였다(표 5 참조), 또한 이때 대장관의 상태를 관찰시 정상 대조군과 각 시료는 맹장과 직장내 잔존물이 거의 없었으며, 정상대조군에서는 잔존 내용물이 많았고 비교예는 약간 있었다. 이러한 결과는 배변량 및 대장내 잔변의 개수와 일관성이 있는 결과로서 실시예가 특별하게 뛰어난 항 변비 효과가 있음을 확인할 수 있었다.As a result of the above experiment, the average number of stools in the control group was 5.0, compared to 1.80-2.00, which was significantly reduced in the Example (see Table 5). There were almost no rectal residues, and the normal control group had a lot of residual contents, and there were some comparative examples. These results were consistent with the amount of defecation and the number of residual stools in the large intestine, and it was confirmed that the Example had a particularly excellent anti-constipation effect.
또한, 대장관내 점액질 분비를 관찰하기 위해 조직검사를 통한 점액질 분비세포와 점액질층을 관찰한 결과를 다음 표 6에 나타내었다.In addition, the results of observing the mucous secreting cells and the mucous layer through the biopsy to observe the mucin secretion in the large intestine are shown in Table 6 below.
±3.9816.7
±3.98
±4.1216.6
±4.12
±4.1816.8
±4.18
±3.4513.5
±3.45
±3.0713.8
±3.07
±4.1113.4
±4.11
(2) 실시예와 비교예 시료는 정상대조군 대비 p<0.01임(1) The mucin thickness is expressed as the mean ± standard deviation (16.7 ± 3.85 for the normal control group)
(2) Samples of Examples and Comparative Examples were p < 0.01 compared to the normal control group
그 결과, 실시예 투여군은 정상대조군이나 비교예 투여군보다 점액분비세포가 활성화되어 점액질의 분비가 원활하고 점액질 두께도 변비 유발군보다 현저히 증가되어 있는 것으로 확인되었다. 정상 대조군의 점액질 두께는 16.0 ㎛로서, 변비 유발군은 정상대조군보다 크게 감소한 12.3㎛의 두께를 가진 반면에, 실시예의 경우 16.6-16.8 ㎛로 정상 대조군 수준을 보였다.(표 6 참조). 반면에 비교예의 경우 정상 대조군과 유사한 정도 수준에 불과하였다.As a result, it was confirmed that the Example-administered group had more activated mucus-secreting cells than the normal control group or the Comparative Example-administered group, so that the secretion of mucus was smooth and the mucus thickness was significantly increased compared to the constipation-inducing group. The mucus thickness of the normal control group was 16.0 μm, and the constipation-inducing group had a thickness of 12.3 μm, which was significantly reduced compared to the normal control group, whereas the Example showed a normal control level of 16.6-16.8 μm (see Table 6). On the other hand, in the case of the comparative example, it was only at a level similar to that of the normal control group.
이러한 실험결과로부터, 실시예의 조성물은 점액질을 크게 증가시켜 장관내 윤활이 유지되고 장관운동을 증가시켜 변비증상을 완화시킴은 물론 장 건강에 크게 우수한 효과를 보이는 것으로 확인되었다. 이로 인해 장 운동이 원활하고 건강개선 효과로 갱년기 장애 극복에 도움이 될 것으로 예측된다.From these experimental results, it was confirmed that the composition of Examples significantly increased mucus to maintain intestinal lubrication and to increase intestinal motility to relieve constipation symptoms as well as exhibit a significantly excellent effect on intestinal health. As a result, it is expected that the bowel movement will be smooth and the health improvement effect will help overcome menopausal disorders.
실험예 5 : 혈청 중 지단백질 함량 분석Experimental Example 5: Analysis of lipoprotein content in serum
실험동물로서 스프라그-도울리 종의 수컷(159∼168 g) 흰쥐를 7 마리씩 4 군으로 다음과 같이 실험하였다. 정상군에게는 일반 사료를 제공하고, 대조군은 고지방 식이군으로 전체 열량의 40%를 지방 열량으로 조성한 사료를 제공하였다. 실험군은 고지방 식이에 실시예 6의 조성물을 고형으로 환산하여 각각 5% 및 10% 첨가되도록 사료를 제조하여 제공하였다. 물과 식이는 자유롭게 섭취할 수 있도록 하였다.As experimental animals, male Sprague-Dawley (159-168 g) rats were tested in 4 groups of 7 rats each as follows. A normal diet was provided to the normal group, and the control group was provided with a high-fat diet group, which consisted of 40% of total calories as fat calories. The experimental group was provided with a feed prepared so that 5% and 10% of the composition of Example 6 was converted into solids, respectively, added to the high-fat diet. Food and water were provided freely.
20 일간의 실험식이 후, 마우스를 12 시간 동안 절식시키고 에틸에테르로 마취시킨 후 개복하여 1 회용 주사기를 이용하여 심실에서 혈액을 채취하였다. 채취한 혈액을 3,000 rpm으로 20 분간 원심 분리하여 얻은 혈청을 시료로 사용하였다. 혈청의 지질 성분인 총 콜레스테롤, 트리글리세라이드, LDL 및 HDL, ALT 및 AST를 각각 통상의 방법에 따라 측정하였다.After 20 days of experimental diet, the mice were fasted for 12 hours, anesthetized with ethyl ether, and then opened and blood was collected from the ventricles using a disposable syringe. Serum obtained by centrifuging the collected blood at 3,000 rpm for 20 minutes was used as a sample. Total cholesterol, triglyceride, LDL and HDL, ALT and AST, which are lipid components of serum, were measured according to a conventional method, respectively.
그 결과, 대조군의 전체 콜레스테롤 함량은 정상 식이군에 비해 27.2% 증가하였으나, 5% 실험군 및 10% 실험군에서는 그에 비해 각각 32% 및 8% 감소하였다. 또한, 5% 실험군 및 10% 실험군에서 저밀도 지단백질은 각각 74.28% 및 35.29% 감소하였다. 반면, 트리글리세라이드, ALT 및 AST는 거의 변화하지 않았다. As a result, the total cholesterol content of the control group increased by 27.2% compared to the normal diet group, but decreased by 32% and 8%, respectively, in the 5% experimental group and 10% experimental group. In addition, in the 5% experimental group and 10% experimental group, low-density lipoprotein was reduced by 74.28% and 35.29%, respectively. On the other hand, triglycerides, ALT and AST were almost unchanged.
이러한 결과는 실시예 6의 조성물이 혈청 중 총 콜레스테롤 및 저밀도 지단백질 함량을 낮추어 각종 심혈관계 질환 등에 효과적으로 사용될 수 있음을 의미한다. 이로 인해 전반적인 건강 기능이 좋아짐으로, 갱년기 증상 개선에 도움이 될 것으로 예측된다.These results mean that the composition of Example 6 can be effectively used for various cardiovascular diseases and the like by lowering the total cholesterol and low-density lipoprotein content in the serum. As a result, overall health functions are improved, which is expected to help improve menopausal symptoms.
또한, 본 발명의 조성물은 간기능의 지표인 ALT 및 AST에는 영향을 미치지 않았으므로 간에는 영향을 미치지 않는 것으로 확인되었다. 그러므로 독성은 없는 것으로 판단된다.In addition, since the composition of the present invention did not affect ALT and AST, which are indicators of liver function, it was confirmed that it did not affect the liver. Therefore, it is judged that there is no toxicity.
Claims (12)
A plant-natural complex component composition comprising 10-90% by weight of Japanese cypress tree and 10-90% by weight of chastity tree as an active ingredient for alleviating or improving female menopausal symptoms.
[Claim 2] The composition of claim 1, further comprising hops.
The method according to claim 1, 60-90% by weight of natural ingredients, 1-35% by weight of prebiotics. A vegetable natural complex composition containing 0.1-3% by weight of zinc and 0.1-3% by weight of vitamins.
[Claim 6] The composition of claim 1, 2 and 5, wherein the composition is for improving vaginal keratosis, vaginal dryness, or vaginal pH.
A health supplement for improving vaginal keratosis, vaginal dryness, or vaginal pH, comprising the vegetable natural complex composition according to any one of claims 1, 2 and 5.
A pharmaceutical composition for improving or treating gynecomastia symptoms for vaginal keratosis, vaginal dryness, or vaginal pH improvement, comprising as an active ingredient the vegetable natural complex composition according to any one of claims 1, 2 and 5.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020190178987A KR102338119B1 (en) | 2019-12-31 | 2019-12-31 | Hub complex composition |
| PCT/KR2020/019318 WO2021137587A1 (en) | 2019-12-31 | 2020-12-31 | Composition for improving or preventing menopausal symptoms, including vitex agunus-castus extract as active ingredient |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020190178987A KR102338119B1 (en) | 2019-12-31 | 2019-12-31 | Hub complex composition |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20210086854A KR20210086854A (en) | 2021-07-09 |
| KR102338119B1 true KR102338119B1 (en) | 2021-12-15 |
Family
ID=76865017
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020190178987A KR102338119B1 (en) | 2019-12-31 | 2019-12-31 | Hub complex composition |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR102338119B1 (en) |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20110004603A (en) | 2009-07-08 | 2011-01-14 | (주)노바셀테크놀로지 | Extracts from sophora japonica l. for treating or preventing menopausal complaints, skin-aging, or skin wrinkle |
| US9775874B1 (en) * | 2012-09-28 | 2017-10-03 | The Daily Wellness Company | Method for treating symptoms of hormone imbalance |
| KR102065934B1 (en) | 2018-03-28 | 2020-01-14 | 농업회사법인 주식회사 황칠코리아 | Composition for prevention and treatment of climacteric disorder comprising extracts of Dendropanax morbifera and Rhynchosia Nulubilis |
-
2019
- 2019-12-31 KR KR1020190178987A patent/KR102338119B1/en active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| KR20210086854A (en) | 2021-07-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Bogdanov | Pollen: Nutrition, functional properties, health | |
| CN105380051B (en) | A kind of anti-alcohol and liver-protection beverage and preparation method thereof | |
| CN110447902B (en) | Composition with weight-losing effect | |
| Baek et al. | Randomized, double-blind, placebo-controlled trial of'Ficus carica'paste for the management of functional constipation | |
| KR102049440B1 (en) | Composition for preventing and improving woman climacterium symptoms comprising extract of Polygonum cuspidatum Sieb. et Zucc. and Cinnamomum cassia Blume | |
| CN115317574A (en) | Composition for treating hyperuricemia and application thereof | |
| KR100549089B1 (en) | A Health Care Composition for treating or preventing intestinal disease and constipation | |
| EP1583547B1 (en) | Anti-obesity ingredients from medicinal plants and their composition | |
| KR100831621B1 (en) | The plant extracts composition for the blood glucose reducing action | |
| KR102338119B1 (en) | Hub complex composition | |
| CN1127349C (en) | Antilipemic slimming tea prepn | |
| KR101822834B1 (en) | Composition for improving menopausal symptom | |
| KR101511364B1 (en) | Herbal Extract Composition for Prevention or Treatment of Obesity and Metabolic Syndrome Using Herbal Extract | |
| JP4993817B2 (en) | Bone metabolism improving agent and food for preventing or treating osteoporosis | |
| CN107432889A (en) | Menopause symptom or osteoporosis improvement composition | |
| Mahboubi | Prunus domestica as effective and acceptable treatment for stool softening and relief of constipation symptoms. | |
| KR20210086851A (en) | Natural plant composition containing probiotics | |
| KR20220033155A (en) | Hub complex composition | |
| KR20210085672A (en) | Hub complex composition | |
| Brice-Ytsma et al. | Herbal Medicine in Treating Gynaecological Conditions | |
| KR100450055B1 (en) | Food composition for improving physical constitution containing seeds of bean plants as main components, and food produced therefrom | |
| KR20210085665A (en) | Health promotion composition containing Plantago Seed | |
| KR20100102366A (en) | Composition of assitant healthful food | |
| KR101855820B1 (en) | Composition for improving hepatic function and enhancing stamina | |
| CN105770134A (en) | Traditional Chinese medicine for treating hyperlipemia |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AMND | Amendment | ||
| E601 | Decision to refuse application | ||
| AMND | Amendment | ||
| X701 | Decision to grant (after re-examination) | ||
| GRNT | Written decision to grant |